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Chronic respiratory diseases affects many people worldwide with little known 
about the mechanisms diving the pathology, making it difficult to find a cure. Improving 
the understanding of smooth muscle and extracellular matrix (ECM) interaction is key to 
developing a remedy to this leading cause of death. With currently no relevant or 
controllable in vivo or in vitro model to investigate diseased and normal interactions of 
small airway components, the development of a physiologically relevant in vitro model 
with comparable cell attachment, signaling, and organization is necessary to develop new 
treatments for airway disease. The goal of this study is to create a mechanically, 
biologically and structurally relevant in vitro model of small airway smooth muscle tissue. 
Synthetic Poly-L-Lactic Acid (PLLA) and decellularized pig lung ECM (DPLECM) were 
electrospun to form nanofibrous mats that can closely mimic natural bronchial tissue. The 
addition of DPLECM significantly changed the PLLA scaffold mechanically, biologically, 
and physically to bring it closer to the characteristics of the human lung. DPLECM 
scaffolds exhibited a significant decrease in the elastic modulus compared with PLLA 
alone. Histological staining and SDS-PAGE showed that after scaffold fabrication, 
essential proteins or protein fragments in natural ECM are still present after processing. 
Human bronchial smooth muscle cells (HBSMCs) seeded onto PLECM scaffolds formed 
multiple layers of cells compared to scaffolds composed solely of PLLA. Phenotype of 
smooth muscle is better maintained when DPLECM is incorporated into the scaffold 
shown by enhanced contractile protein expression and increased collagen production for 
normal smooth muscle remodeling of the scaffold. In summary, this research demonstrates 
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that a PLLA/DPLECM composite electrospun mat is a promising tool to produce an in 
vitro model with the potential to uncover unknown characteristics of bronchiole smooth 
muscle behavior in diseased or normal states.  
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CHAPTER 1: INTRODUCTION 
Airway Anatomy and ECM 
 The structure of the lungs consists of many branched airways that allow for air to 
travel to the alveoli for gas exchange while being heated and conditioned. The first region 
of branching is considered the conducting zone and consists of the trachea, bronchi, and 
the bronchioles. The final zone is responsible for gas exchange and is therefore called the 
respiratory zone comprised of respiratory bronchioles, alveolar ducts and alveoli [1]. 
The natural cellular population within the respiratory tract is lined with ciliated 
cells which are pseudostratified columnar in the upper airways and cuboidal closer to the 
terminal bronchioles. Ciliated cells function as a defense system, moving debris and mucus 
from the airways by pulsatile beating. Interspersed with the ciliated cells in the larger 
airways, there are goblet cells that are responsible for mucus secretion. Moving to the 
smaller airways, these cells are replaced by Clara cells that secrete other proteins such as 
surfactant and inflammatory molecules [2]. Another type of cell found in the airways are 
mast cells that are involved in the secretion of many inflammatory mediators to cause 
bronchoconstriction, mucus secretion, and modifying the permeability of the surrounding 
blood vessels [2]. In the alveoli, the epithelial layer is composed of squamous type I 
alveolar cells with fewer cuboidal type II alveolar cells [2]. Type II alveolar cells are 
progenitor cells for alveolar type I epithelium [1] and also produce surfactant to reduce 
surface tension within the alveoli. 
5 
  
Airway structure closely resembles the cardiovascular system in that they are 
designed to withstand shear forces created by air instead of blood and with smooth muscle 
contraction to control the movement and pressure [3]. ECM components and their 
placement around the airways are important to keep a constant airway compliance for 
natural airway physiology. The airway walls are divided into layers. The first layer is the 
mucosa that surrounds the lumen of the airway. It is comprised of epithelium, basement 
membrane, and subepithelial collagen [4]. The basement membrane lies directly 
underneath a layer of epithelial cells and is composed of collagen type-IV, laminin, 
entactin/nidogen, and heparin sulfate [3]. Beyond the basement membrane, there is a 
section in the mucosa composed of collagen type III and V and laminin that is considered 
the subepithelial collagen. This section functions to give structural support to the airways 
[3]. Beyond the mucosa layer there is the submucosa layer that is comprised of mostly 
collagen, elastin, and proteoglycans and is the region where most fibroblasts and smooth 
muscle cells are found [3]. The overall organization of the cells and structural proteins as it 
progresses down the airways to the alveoli can be seen in Figure 4.  
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Figure 1: Airway wall organization. Airway wall cross-section showing organization 
of cells and connective tissue from the trachea to the alveoli. Produced with permission 
from [4]. 
Asthma and COPD 
Two major debilitating obstructive airway diseases are bronchial asthma and 
chronic obstructive pulmonary disease (COPD). Asthma currently effects 300 million 
people worldwide with expectations for it to effect 400 million people by 2025 [5]. COPD, 
similarly, is expected to become the third leading cause of death by 2020 [6]. Both of these 
diseases are characterized by a severe inflammatory response to allergens and structural 
remodeling of the airway wall leading to chronic symptoms [6], [7].  
A factor distinguishing asthma from other airway diseases is the reversibility of the 
airway narrowing with removal of activity and allergens or medications [8]. Asthma 
affects all conducting airways of the lungs with over stimulation of the airway smooth 
muscle (ASM), severe inflammation, and mucus secretion causing constriction of airflow 
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and difficulty breathing [9]. These pathologies are in response to various internal and 
external stimuli including airborne allergens, infection, exercise, cold air, smoke, beta 
blockers, and stress [9], [10]. If left untreated, asthma can cause many more irreversible 
changes in lung tissue. Edema is a key component of prolonged asthma, it is initiated when 
long term inflammation dilates blood vessels causing fluid and protein leaking into the 
surrounding tissue [11]. If edema and inflammation persists, fibrosis may develop with 
even more weakening symptoms. Smooth muscle modulation is another key prolonged 
effect of asthma. Inflammatory cells release signaling molecules that can stimulate smooth 
muscle growth, hyperactivity [11], and remodeling of the structural elements of the lung 
[9]. Asthma can be difficult to treat and study because of the variation between patients. 
Since there are many different causes and responses to therapy, there is a large impact of 
genes on the asthmatic response [9].  
COPD, in comparison, is a term that encompasses emphysema, chronic bronchitis 
and some bronchiectasis, but mostly describes irreversible airway limitation caused by 
abnormal inflammatory response to environmental factors or genetic signaling [12], [13]. 
Differing from asthma, COPD occurs almost exclusively in the smaller airways, making it 
less accessible for biopsies [13]. Most symptoms that contribute to the inflammatory 
response include structural changes of small airway ways such as epithelial metaplasia, 
increased ASM mass, goblet cell increase, and submucosal gland hypertrophy and 
secretion [13]. In comparison to asthma, COPD is much less understood from the 
perspective of the molecular mechanisms that drive the pathology. Diagnosis of COPD 
from asthma is usually distinguished by lung functional testing or if patient has exposure to 
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environments with toxins known to cause COPD [6]. Lung testing is done to examine the 
ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) [6]. 
In this ratio, there is a significantly decreased FEV1 [13] causing the patient to exert more 
force to inflate the lungs. Individuals can also be diagnosed based on the risk factors 
caused by prolonged inhalation of noxious gases, smoking, or toxic gasses or pollution [6]. 
Although there are many overlapping symptoms between the two diseases there are 
many differences still undiscovered. The major difference between the two diseases is seen 
in the inflammatory response, airway hyperresponsiveness [6], [14] and cellular recruiting. 
Summary of similarities and differences between COPD and asthma, in airway 
remodeling, symptoms, and inflammatory response are seen in Figure 2. One of the largest 
gaps in information in both diseases is the inflammatory characteristics that differ between 
the two [15]. The differences in inflammatory response are easily seen by the recruitment 
of different inflammatory cells and mediators to the airways at different times. Asthma has 
an increased number of activated CD4+ T-lymphocytes, eosinophils, and mast cells while 
in COPD there is an increased number of CD8+ T-lymphocytes, macrophages and 
neutrophils [15], [16]. Although these differences are prevalent, there is much more to be 
discovered about the cellular and molecular mechanisms driving asthma and even more to 
be understood about COPD [15], [17]. By unveiling the mechanisms behind these diseases, 
opportunities will arise for pharmacological solutions. Asthma’s symptoms are typically 
managed with corticosteroid therapy, but there is no specific treatment for COPD and 
therefore is treated as a less responsive form of asthma [15]. To increase the knowledge 
9 
  
and therefore cures for these diseases, a more feasible option to study diseased and natural 
states in these regions needs to become available.  
 
Figure 2. Similarities and differences between COPD and Asthma with respect to 
inflammatory response, airway wall changes, and symptoms. Reproduced with permission 
from [16].  
Airway Smooth Muscle Background 
Airway smooth muscle (ASM) plays a key role in lung homeostasis and disease 
pathologies. It is found from the trachea to the terminal bronchioles and is responsible for 
bronchomotor tone [17]. From a physiological prospective, there is no imperative purpose 
for airway smooth muscle dilation, the only function of ASM seems to be an undesirable 
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pathological drawback [18]. Change in structure and arrangement from the upper airways 
to lower airways is seen in various ways. In the upper airways, ASM is found attached to 
the cartilage in the posterior region while in the lower airways it is seen in a helix-antihelix 
arrangement around the bronchi [17]. There has also been research to show that there is a 
difference in the distribution of B-adrenergic receptor expression in the two regions [17], 
possibly giving foresight into why asthma occurs in all regions of the lung but COPD 
mostly only occurs in the lower airways. The complexity and specialization of ASM in 
various regions, lead us to believe there is a purpose for its contraction that has not yet 
been discovered and it differs from region to region.  
The basic mechanisms of ASM contractility include the well-known actin myosin 
crossbridge cycling present in all muscle types but there is also a more complex interaction 
of the actin filaments with extracellular proteins. Actin filaments indirectly bind to 
membrane adhesion plaques through molecular complexes, such as alph-actinin, talin and 
filamin. It is those molecular complexes that bind to adhesion plaques, which then bind to 
integrin proteins of the ECM in the configuration seen in Figure 3, to transmit external 
forces inside of the ASM cells [19]. 
11 
  
 
Figure 3. Airway smooth muscle cytoskeletal protein arrangement and attachment to ECM 
molecules. A) Arrangement of Actin and myosin within the cell and overview of actin 
attachment to membrane adhesion complexes and ECM. B) Detailed binding of Actin 
filaments indirectly to adhesion complexes and ECM proteins through various molecules. 
Reproduced with permission from [19]. 
ASM can create metalloproteinases to destroy old matrix and then lay down 
various ECM proteins. The ratio and abundance of ECM proteins can differ in ratio and 
abundance based on the inflammatory and mechanical signals it is receiving from the 
environment [17]. If signals for disease have been transcribed in the ASM cells during a 
diseased state, it can encourage ASM growth as well as ECM production with qualities 
12 
  
different from normal airway ECM. Cellular differentiation is specifically modulated by 
ECM through variations in mechanical forces transduced by adhesions sites [17].  
 Major phenotypic changes can be seen in ASM during diseased states based on 
surrounding environment including the contractile protein expression such as alpha-actin, 
myosin heavy chain, and calponin [20], [21]. A more undifferentiated mesenchymal 
phenotype is seen from ASM exposed to unusual structural properties or signaling profile 
such as those seen in COPD and Asthma [17], [20].  Research has shown that ECM 
components such as laminin and collagen type IV can prolong the contractile phenotype of 
ASM cultured in vitro, as well as keep normal proliferation levels as compared to cells 
seeded without vital ECM components [20], [21]. 
Overall it is understood that ASM is drastically influenced by mechanical forces, 
ECM signaling, and inflammatory signaling. Any modulation to these factors can influence 
the expression of phenotypic markers, leading to airway disease such as asthma or COPD. 
There has been evidence that ASM undergoes modulation in diseases such as asthma and 
COPD [17]. Many factors affect the narrowing of the airways involved in asthma but there 
have been shown to be abnormalities in airway smooth muscle structure and function and 
increased smooth muscle mass causing smooth muscle hyperresponsiveness [8]. Because 
of ASMs influence on the homeostasis of airway tissue, fully understanding the 
modulating factors may create more opportunities for therapy.  
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Figure 4: Overview of ASM phenotypic modulation through abnormal environmental 
stimulation during diseased states, highlighting the region of therapeutic intervention from 
signaling pathways to gene regulation. Reproduced with permission from [17]. 
Current Strategies for Airway Modeling 
Current studies associated with COPD and asthma lack a good animal model 
affecting the possible level of understanding of the cellular and molecular mechanisms 
driving ASM hyper-reactivity. Data we have today focuses on research with whole airways 
or investigations of isolated monolayered ASM cells. There are downfalls of both 
approaches including the lack of biological insight with whole airway sample and the 
deficiency of structural and environmental ques in a single cell investigation. Platforms for 
lung tissue modeling presently lack several key physiological characteristics existing in the 
natural lung. These are commonly studied on two dimensional tissue culture plastic or 
other two dimensional rigid surfaces lacking the proper environment of natural tissue. 
14 
  
Creating a reliable and accurate in vitro model of the small airways has rarely been done 
and will offer a controllable and highly observable platform for studying intracellular 
pathways in normal tissue remodeling and diseased states. Another benefit of completing 
this goal is to decrease the reliance on animal models for cost and moral purposes. This 
method enables the use of human cells in vitro, which have proven more accurate than the 
use of mice or other animals with physiological and anatomical differences [17].   
A useful strategy when modeling a cellular environment is to closely mimic the 
surrounding ECM. One effective way to imitate the structure of ECM is through 
electrospinning. Electrospinning is a highly controllable and versatile technique using high 
electric potentials to develop nano or mico sized fibers that mimic natural fibers 
throughout the human body [22]. More specifically, the polymer solution is forced out of 
the needle tip by an electrical charge differential until a Taylor cone is formed and creates 
a stream of fluid directed towards the grounded target as seen in Figure 5. This technique 
creates fibers ranging from a few nanometers to micrometers, which resembles the range of 
fiber diameter has to natural ECM protein diameter and arrangement [23]. This fiber 
distribution makes it an attractive process for tissue engineering. There are many variations 
that can be added to the electrospinning process to tailor it for different applications. 
Changes in characteristics such as fiber size, alignment, mechanical properties or porosity 
[24] can be changed by varying parameters of the electrospinning set up. To create a 
nanofibrous scaffold with random alignment the set up shown in Figure 5 is used. When 
layered randomly into a three dimensional mat, the resulting scaffold has a highly porous 
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architecture allowing nutrient movement, cell infiltration, and a multiaxial mechanical 
strength.  
 
 
Figure 5: Conventional electrospinning set up. Plastic syringe containing polymer and 
volatile solvent solution that is to a voltage supply, to create a Taylor cone and jet of 
polymer to deposit onto a grounded metal mandrel. A randomized fibrous mat is created as 
seen by SEM. Reproduced with permission from [25]. 
 Variations to the basic electrospinning process allows for the application of this 
process to a broad range of uses. For example, the choice of material can change 
mechanical properties, bioactivity, and electrospinning parameters. When making a viable 
cellular model, the first goal is to create a biologically active material with strength similar 
to that of natural lung tissue. This can be done by combining a naturally derived substance 
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with a synthetic polymer. Incorporating natural ECM substances into scaffolds have the 
potential to promote constructive tissue remodeling after injury in many areas of tissue 
engineering including vascular [26], skeletal muscle [27], and central nervous systems[28]. 
These materials offer more similarities to lung tissue than exclusively synthetic scaffolds 
because of the cellular attachment and tissue-specific signaling that take place with natural 
extracellular matrix (ECM) proteins (i.e. collagen, elastin, fibronectin, and laminin). 
Research has been done incorporating collagen [29], [30], gelatin [31], fibrinogen [32], and 
many other combinations of natural proteins to increase biocompatibility. Cellular 
recognition of the native tissue ECM decreases inflammatory response to create the 
environment needed for constructive remodeling [33]. Specifically, the degradation 
products generated by the ECM proteins recruit cells and induce proliferation that 
encourages scaffold remodeling [34].  
The cell-matrix interaction can also be optimized by tailoring the fiber size to 
mimic the environments surrounding specific cell types. For example, epithelial tissue 
prefers a dense, smaller fiber scaffold to resemble the basement membrane. In comparison, 
smooth muscle cells and fibroblasts prefer a larger fiber diameter with increased porosity 
[35]. There has been research creating models using this idea that different cells need 
different structural environments. In research that includes more than one cell type, 
variations in structural environments were achieved with biphasic scaffolds [35], [36]. 
It is also important to note that ECM is not uniform across all tissue in the body, and 
the dissimilarities determine cell behavior including the activation or deactivation of 
internal cell signaling [28]. Studies have shown that the origin of the natural ECM will 
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change MSC phenotype towards a lineage native to the original organ [37]. There is an 
ongoing feedback loop between the cells laying down ECM specific to cell phenotype and 
the ECM signaling the cells towards a specific tissue phenotype [27]. In this research we 
propose that for these reasons, decellularized porcine lung ECM would offer the 
appropriate signaling for proper phenotypic expression of lung cells [38]. To increase the 
mechanical strength that DPECM lacks, PLLA will be added to form a composite material 
to also offer, biocompatibility and workability.  
Objectives: 
The advantages of natural extracellular environment have been exploited in this study 
by incorporating decellularized ECM into electrospinning of an FDA approved, 
biodegradable [41] synthetic polymer. This offers customizable nanostructure, mechanical 
profile, and degradation properties with practical biological signaling optimized for an 
accurate human analog for smooth muscle function in the airways. This research aims to 
characterize the mechanical and microstructural properties of a naturally derived lung 
ECM and Poly-L_Lactic Acid (PLLA) electrospun nanofibrous fabric. The basic cell-
scaffold interactions were examined with native lung cells to assure its future success. 
Confirming these properties could establish this material as a medium that stimulates 
lineage and tissue-specific interactions for airway cells. The goal of this study was to 
create a scaffold electrospun with PLLA and decellularized pig lung ECM (DPLECM) 
possessing increased biocompatibility compared to a PLLA scaffold.   
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Specific Objectives: 
1. Fabricate PLECM/PLLA electrospun scaffold with randomized nanofibers. 
2. Characterize properties of the scaffold.  
a. Assess fiber size through quantification of SEM images. 
b. Perform tensile testing on wet scaffolds with and without cells to compare 
to natural lung tissue. 
c. Asses hydrophobicity off electrospun scaffolds with PLECM to compare to 
PLLA only scaffolds 
d. Confirm the presence of ECM proteins or protein fragments after exposure 
to Hexafluoro-2-propanol (HFP) and electrospinning. 
3. Assess biocompatibility by culturing primary cell lines 
a. Compare ASM cell attachment and morphology on scaffolds containing 
PLECM to pure PLLA scaffolds. 
b. Evaluate gene expression changes and morphology of ASM to confirm the 
maintenance of contractile phenotype in PLLA/PLECM model. 
 
 
 
 
19 
  
CHAPTER 2: Materials and Methods  
2.1 Overview of Experimental Design. 
 Extracellular matrix (ECM) was extracted from porcine lungs, decellularized and 
pulverized through chemical and physical means to obtain an ECM powder. The ECM was 
then dissolved into hexafluoro-2-propanol (HFP) and Poly-L-lactic acid (PLLA) solutions 
at various concentrations and electrospun into a thin fibrous mat. Fibers and overall 
scaffold were characterized and evaluated for strength and biocompatibility with Human 
Bronchial Smooth Muscle Cells (HBSMCs). Optimum ECM/PLLA concentrations were 
previously found based on strength and ability to properly electrospin. All data is 
compared to a control of 100% PLLA nanofibers created under similar electrospinning 
parameters. 
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Figure 6: Processing steps of porcine lung tissue from cellular whole lung, depicted on the 
top left to a nanofibrous mat shown on the bottom right. The process starts with a chemical 
decellularization process to give a decellularized whole lung seen at the top left which is 
then physically milled to obtain a powder that is put into a PLLA/ECM/HFP solution seen 
at the bottom left. The solution is then electrospun into thin mats seen in the bottom center 
which are composed of nanofibers visible by SEM at the bottom right. 
2.2 Porcine Lung Decellularization and Preparation  
2.2.1 Tissue Decellularization. 
 Pig lungs (donated from Smithfield Hams) were decellularized by established 
protocol [39], [40]. The lung was perfused through the trachea and vasculature with sterile 
water containing penicillin/streptomycin (Life Technologies), before being drained 
passively. The lungs were then perfused with 0.1% Triton X-100 (Fisher Scientific) and 
submerged overnight before rinsing again with the water and penicillin/streptomycin 
solution. The lung was perfused with a 2% sodium deoxycholate (Sigma) solution for 24 
hours, then directly filled with a DNase solution for one hour. The lung was rinsed before 
adding sodium chloride (Fisher Scientific) for one hour.  All debris and agents were 
removed by rinsing with water and the 1X PBS five times. All tissue was then dissected to 
remove larger, cartilaginous airways and cut into smaller chunks for processing. 
Processing of the decellularized tissue to achieve a fine powder included lyophilizing and 
freezer milling using a SPEX 6700. Powder was kept at -80° C until used put into 
electrospinning solution. 
2.2.2 Scaffold Fabrication.  
21 
  
Scaffold was optimized by changing working distance, flow rate, needle size, and 
PLLA concentration. Resulting scaffolds were carbon coated and observed by Scanning 
Electron Microscope (SEM, Hitachi SU-70 FE-SEM). A final solution of 140mg of 
powdered PLECM was combined with 3 mL Hexafluoro-2-propanol (HFP) and mixed for 
24 hours on a vortexer. 400 mg PLLA in 1 mL of HFP was mixed for the same period of 
time. The PLECM solution was poured into a syringe and pushed through a 150x150 mesh 
count stainless steel type 304 wire cloth into the PLLA solution to remove any large 
clumps of ECM that were not in solution. The mixture was then vortexed again for an hour 
to create the final PLLA/PLECM/HFP solution. Pure PLLA control solution was made by 
adding 400 mg PLLA to 4 mL of HFP and vortexed for one hour. Solutions with 35 mg 
and 0 mg PLECM with 100mg PLLA per mL HFP were electrospun onto a rectangular 
mandrel, 27 cm away from the needle and a rate of 4.5 mL/hr. 35 mg/mL PLECM 
solutions were electrospun with a voltage of 27kV and the PLLA only was electrospun 
with a voltage of 15kV, which were arrived at by the establishment of a stable Taylor cone. 
2.3 Acellular Scaffold Characterization.  
2.3.1 Scaffold Architecture 
Scaffolds with various concentration of ECM were dried in a desiccator for a 
minimum of 24 hours before sputter coating for 60 seconds. Scaffolds were imaged with 
Scanning Electron Microscopy (SEM, Hitachi SU-70 FE-SEM) to show fiber size and 
architecture. Decellularized ECM tissue without processing was also sectioned and carbon 
coated after lyophilization for SEM imaging. Average fiber diameter and distribution of 
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the scaffolds were determined by taking measurements of 200 plus fibers per image, within 
three images of each scaffold type. 
2.3.2 Mechanical testing 
Elastic properties of PLLA scaffolds with varying amounts of PLECM (35 mg/mL 
and 0 mg/mL), with and without cells were tested using MTS Bionix 200 with TestWorks 
4.0 Software, using established tensile testing protocols. Samples were taken from various 
scaffolds produced on different dates to cover batch to batch variability. Scaffolds without 
cells were wet for one week with Smooth Muscle Basal Media (SmBM, Lonza) to simulate 
physiological wet conditions. Scaffolds with cells were cultured for one week in a 24 well 
plate with dog bone shaped scaffolds held to the bottom of the wells with o-rings (Aflas). 
50,000 HBSMCs (Lonza) were seeded onto each dog bone with Smooth Muscle Growth 
Media (SmGM, Lonza), changed every two days.  
2.3.3 Contact Angle Measurement.  
Wettability of the composite nanofiber mat was determined using the sessile drop 
method with an OCA 15 Goniometer with controlled automatic liquid deposition and a 
computer based image processing system. 5 µL of dH2O were deposited onto the fiber 
meshes with varying concentrations of PLECM. Each concentration type was repeated 4 
times and the average contact angle was taken.  
2.3.4 SDS-PAGE 
SDS-page of scaffold proteins was performed to determine which ECM proteins 
and how much of each were present in the scaffolds post decellularization and 
electrospinning. 100 mg of intact tissue, 100 mg of decellularized tissue, and 200 mg of 
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each scaffold were put into a mixture of 1% SDS, 25 nM Tris, and 4.5 M Urea and heated 
to 60⁰C for one hour, to increase the amount of protein re-suspended. The loading 
efficiency of DPLECM into the electrospun scaffold was determined using the final weight 
of the scaffold and ratio of PLLA and DPLECM in the solution before electrospinning. 
The yield of pure DPLECM within 200 mg of the 35 mg/mL PLECM/PLLA electrospun 
scaffold was the amount used for both DPLECM powder and DPLECM powder with HFP, 
to compare to the electrospun scaffold. The decellularized pig lung powder treated with 
HFP was allowed to fully evaporate after the HFP soak. Both were then put in 1 mL of the 
1% SDS, 25 nM Tris, and 4.5 M Urea solution and heated to 60⁰C for one hour. Protein 
concentration was measured using a Peirce™ BCA protein assay kit. All samples except 
PLLA, were balanced to the protein concentration of the 35 mg/mL PLECM/PLLA 
scaffold. 11.25 uL of 5 ug/uL protein and 3.75 uL of Laemmli buffer were loaded into each 
well of a 15 well, Mini-PROTEAN TGX stain-free gel (BIO-RAD) and run for 25 minutes 
in a Mini-PROTEAN tetra system (BIO-RAD) with running buffer. Resulting bands were 
imaged using a BIO-RAD gel imager. 
2.3.5 Histology 
Scaffolds were cryosectioned at 10 to 20 µm with a Thermo FSE Cryostat and 
stored frozen. Before staining, slides were heated to 100°C to increase specimen 
attachment. Sections of 35 mg/mL and PLLA only were stained with Masson’s trichrome 
(Sigma) including hematoxylin (Sigma) following manufacturers protocol, to show ECM 
components. Imaging of ECM proteins within the scaffolds was done with the use of a 
light microscope. 
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2.3.6 Collagen and Elastin quantification 
 Elastin and collagen quantification procedure was taken from an established 
protocol [41]. 10 mg of electrospun scaffolds (PLLA and 35 mg/mL PLECM) and 10 mg 
of ECM powder were used for both quantifications. The samples and ECM powder were 
solubilized in 0.1 M NaOH at 98°C for 45 min. The supernatant was removed and 
lyophilized before hydrolyzing for 24 hours in 6M HCL at 110°C. The samples were 
lyophilized again and resuspended in 2 mL of DI water. For the collagen quantification all 
protein was put through a hydroxyproline assay (Sigma). For the elastin quantification, the 
same material samples were quantified with ninhydrin assay according to previously 
published methods [39]. Resulting data for ECM powder was normalized based on loading 
efficiency of the ECM into the polymer. ECM yield was found using the final weight of 
the scaffold and ratio of polymer to PLECM powder. 
2.4 Cell Culture  
2.4.1 Cell and media specifications.  
Scaffolds and coatings were all sterilized with ethanol and rinsed with PBS before 
cultured with cells. HBSMCs (Lonza) were passaged continuously when confluency 
reached 80%. HBSMCs between passages 2-8 were expanded in SmGM (Lonza) with 
medium changed every 48 to 72 hours. All scaffolds were anchored to the bottom of tissue 
culture plates with Aflas-O Rings (24-well plates) or silicone (6-well plates, Loctite).  
2.5 Cell Viability and Proliferation 
2.5.2 Live/Dead Cell Viability Assay  
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HBSMCs were seeded at a density of 50,000 cells onto PLLA and 35 mg/mL 
PLECM/PLLA scaffolds at the bottom of a 24 well plate. After 72 hours in culture, 
reagents were added to label live cells (calcein AM, Thermo Fisher Scientific) and dead 
cells (Ethidium homodimer-1, Thermo Fisher Scientific) according to manufacturer’s 
directions. After incubating in the reagent for 30-45 minutes the samples were mounted 
onto glass slides and imaged with an Olympus IX71 inverted microscope. Each scaffold 
type had three samples with three images taken of each sample. Live and dead images were 
combined and quantified using Image J analysis.  
2.5.3 Qualitative SEM Imaging 
 200,000 HBSMCs were seeded onto 24-well sized scaffolds and cultured for one 
week. All samples were rinsed with PBS before fixing with 4% paraformaldehyde for a 
minimum of 20 minutes and rinsed again with PBS. After the initial fixation, the samples 
were put through secondary fixation with osmium tetroxide for one hour. To remove water, 
samples were ethanol dehydrated for critical point drying. The samples were dried using a 
Tousimis Critical point dryer, carbon coated for 60 seconds, and imaged using a JEOL 
JSM-5610LV SEM. 
2.6 Cell phenotype 
2.6.1 qPCR 
Gene expression of 1,000,000 HBSMCs seeded onto scaffolds or coatings of 
various concentrations PLLA and PLECM for one week were quantified using qPCR. 
Cells and scaffolds were put into 1 mL of TRIzol (Life Technologies) and homogenized 
using 0.5 mm zirconium bead homogenization tubes and a microtube homogenizer 
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(Beadbug) and any remaining chunks of scaffold were removed. RNA was then extracted 
following Trizol manufactures protocol. RNA concentration and quality was quantified 
using a Take3 mircovolume plate (BioTek) and an Epoch reader. RNeasy kit (Qiagen) was 
then used to purify RNA if samples did not have a 260/280 ratio of 2 +/- .3. Using a high 
capacity cDNA reverse transcription kit (Applied Biosystems), balanced RNA was 
converted to cDNA. qPCR was run on CFX connect real-time system (BIO RAD) using 
powerSYBR Green PCR Master Mix (applied Biosystems). The expression of mRNA was 
determined by relative Cq value to zero. Four primers were used including α-SMA, CNN1. 
MYH11, and COL1 A1 (IDT). Primer sequences are listed in Table 1.  
Primer Gene Forward Primer Sequence 
α-SMA Alpha Smooth Muscle Actin 5' CCG ACC GAA TGC AGA AGG A 3' 
CNN1 Calponin 1 5' GTC AAC CCA AAA TTG GCA CCA 3' 
MYH11 Myosin Heavy Chain 11 5' CGC CAA GAG ACT CGT CTG G 3' 
COL1 A1 Collagen 1 A1 5' GTG CGA TGA CGT GAT CTG TGA 3' 
 
Table 1: Primer sequences of contractile genes used in qPCR. 
2.6.2 Immunofluorescence. 
 Scaffolds in a 24-well plate were seeded with 100,000 HBSMCs for one week. 
Scaffolds were fixed with 4% PFA and rinsed with PBS three times. To assess morphology 
and cell-cell connections, scaffolds with cells were stained FITC labeled phalloidin (Cell 
Signaling) according to manufacturer’s protocol and imaged using a Zeiss LSM 710 Laser 
Scanning Microscope.   
2.7 Statistics 
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Unless otherwise stated, GraphPad Prism was used for all statistical analysis. One-way 
ANOVA with Turkey pot-hoc comparisons or T-tests were done when appropriate to 
determine significance. Significance is represented by: *p-value < 0.05, **p-value < 0.01, 
***p-value < 0.005. 
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CHAPTER 3: Results 
3.1 Acellular Scaffold Characterization  
3.1.1 Scaffold architecture 
Fiber size and density were first optimized for smooth muscle cell sustainability by 
tayloring electrospinning parameters. Changes were made in flow rate (Figure 7-C), 
working distance (Figure 7-C,D), needle guage (Figure 7-E), and PLLA concentration 
(Figure 7-F) as compared to Regular 35 mg/mL PLECM (Figure 7-A) and PLLA (Figure 
7-B). The most significant decrease in fiber diameter was seen when PLLA concentration 
was decreased. Any other strategy of changing fiber size did not seem to have any 
significant change in fiber size distribution as compared to scaffolds made from orginial 
electrospinning parameters.  
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Figure 7: Changes in electrospinning parameter to optimieze fiber diameter. Regular 35 
mg/mL PLECM (A) and PLLA (B) are compared to fiber diameter when flow rate was 
changed to 2 mL/hr instead of 4 mL/hour and working distance was changed to 15 cm 
instead of 27cm (C), when only working distance was changed to 6 inches instead of 27 
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cm (D), when needle guage was changed to 23G instead of 19G, and when PLLA 
concentration was decreased to 100 mg PLLA with 140 mg of PLECM instead of 400 mg 
PLLA with 140 mg of PLECM (F). 
 
 Optimized PLLA/PLECM scaffolds were imaged using SEM to examine the 
characteristics of the nanofibers. Electrospinning PLLA and PLLA/PLECM composite 
created a nanofibrous scaffold with the diameter and morphology shown in shown in 
Figure 8A-7D. Electrospinning with our optimized parameters created nanofibers similar 
to the size of the fibers of whole decellularized lung tissue seen in Figure 8E and 8F. The 
most uniform fibers in Figure 8E are seen in the regions where smooth muscle would most 
likely be located below the basement membrane of the airways, shown by the arrow. 
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Figure 8: Scaffold and decellularized tissue fiber thickness. SEM of electrospun A-B) 35 
mg/mL PLECM/PLLA and C-D) PLLA only scaffolds to compare to E-F) Decellularized 
ECM fibers that relate directly to natural fibers found in the airway environment. 
Three SEM images were taken of each scaffold and from those images, 200 or 
more measurements of fiber width were taken. Average fiber thickness for PLLA only 
electrospun scaffolds was found to be 712.4 nm+/- 462.4 nm with a range from 54 nm to 
4702.1 nm. 35 mg/mL electrospun scaffolds had an average fiber diameter of 806.4 nm +/- 
432.1 nm with a range from 232.5 nm to 4783 nm as seen in Table 2. Average scaffold 
thickness was found to be of 139µm+/- 53µm. Fiber distribution (Figure 9) shows the 
majority of fibers to have a diameter from 250 nm to 750 nm. 
 
Average Diameter (nm) STDEV (nm) Min (nm) Max (nm) 
35 mg/mL 806.4 432.1 232.5 4783 
PLLA only 712.4 462.4 54 4702.1 
 
Table 2: Fiber diameter of electrospun scaffolds. 
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Figure 9: Fiber distribution of A) 35 mg/mL PLECM/PLLA and B) PLLA only 
electrospun scaffolds. Range and distribution taken from three images per group with 200 
plus fiber measurements.  
3.1.2 Mechanical testing 
 Uni-axial tensile testing of the PLLA scaffolds with various amounts of PLECM 
after a 1 week soak in basal media was done to determine several mechanical properties 
including elastic modulus, to compare to natural tissue. The addition of PLECM to the 
scaffolds decreased the average elastic modulus by 34.11 MPa. Both scaffolds were 
cultured with HBSMCs for one week to determine the amount of remodeling done to the 
scaffolds and its effect on the elastic modulus. Remodeling by the smooth muscle cells was 
found to have a significant effect on the properties of the scaffolds by decreasing the 
average PLLA scaffold modulus to 16.35 MPa and the ECM modulus to 14.03 MPa. It is 
important to note that many of the 35 mg/mL scaffolds with cells were too weak to be 
loaded into the MTS machine and therefore were untested. For that reason, the resulting 
data only represents the stiffest of the 35 mg/mL scaffolds with HBSMCs. Figure 10 
compares scaffolds with various amounts of PLECM, with and without cells. Overall the 
addition of PLECM significantly decreased the mechanical properties of scaffolds with and 
without cell intervention to more closely mimic the properties of natural tissue as expected.  
35 
  
 
Figure 10: Elastic modulus of electrospun scaffolds. Tensile testing for scaffolds with 
various amounts of PLECM under wet conditions, with and without cells. 35 mg/mL w/ 
HBSMCs and PLLA w/ HBSMCS represent respective scaffolds with HBSMCs cultured 
for one week. Wet 35 and wet PLLA represent scaffolds that have been soaked in media 
for one week without cells. Data are presented as mean +/- st. dev. Sample size varied 
between 4 and 11 per group. 4 of 11 samples show for 35 mg/mL with HBSMCs because 
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of scaffold weakness making some samples untestable. PLLA was significantly greater to 
all other groups. **** p<0.0001 
3.1.3 Contact Angle Measurement.  
 Average results of the resulting water contact angle of a 5µL dH2O drop on the 35 
mg/mL PLECM and PLLA nanofiber composite scaffold and PLLA only scaffold with the 
sessile drop method are shown in Figure 11 and Table 3. Overall the water contact angle 
decreased with increasing PLECM with an average decrease of 14.1° between PLLA only 
and 35 mg/mL PLECM.   
 
 
Figure 11: Contact angle measurements on electrospun scaffolds. 
 
Average Contact Angle Number of Samples 
35 mg/mL PLECM 115.1° +/- 3.5° 4 
PLLA only 129.2° +/- 1.9° 4 
 
 
Table 3: Contact angle measurements of various electrospun scaffolds.  
3.1.4 SDS-PAGE 
PLLA only 35 mg/mL 
PLECM 
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 SDS-PAGE was performed on protein extracted from intact pig lungs, 
decellularized pig lungs, decellularized pig lung powder, decellularized pig lung powder in 
HFP, and scaffolds containing only PLLA and 35 mg/mL PLECM/PLLA, shown in Figure 
12. PLLA was a control to show effects of the polymer alone. The differences between 
decellularized ECM powder and the 35 mg/mL scaffolds highlights the effect that 
electrospinning and the harsh solvents used for electrospinning have on the integrity and 
existence of ECM proteins. Intact tissue has a wide range of proteins resulting in many 
bands, while decellularized tissue has fewer protein bands due to the removal of cells and 
blood that contribute to the vast assortment of proteins. Powdered DPLECM and Powdered 
DPLECM in HFP have similar bands at 25 and 15 kDa but treating with HFP causes many 
larger proteins to be lost or degraded to a smaller protein fragment. A similar amount of 
bands are present in the pure DPLECM powder in HFP and the 35mg/mL PLECM scaffold 
with the exception of a few bands. These results showed no significant bands of protein 
present from PLLA, as expected.   
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Figure 12: SDS-PAGE of electrospun scaffolds vs. intact pig lungs, DPLECM, and 
DPLECM powder.  
3.1.5 Histology 
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 Sections were taken from the various scaffolds using cryosectioning and stained 
with Masson’s Trichrome ECM protein dye. PLLA was used as a control containing no 
ECM proteins but also further demonstrated the regularity of the nanofiber structure 
throughout the scaffolds. After staining 35 mg/mL scaffolds there was prominent amounts 
of collagen, stained purple, and elastin, stained black (Figure 13). While imaging there was 
a large amount of light refracting, causing images to be more distorted than usual. The 
proteins are dispersed throughout the PLECM/PLLA scaffold, with purple showing 
collagen and black showing elastin. The dark purple and black dye is seen throughout the 
scaffold as well as throughout the fiber. Large spots of stained scaffold are likely 
sectioning artifacts, which are confirmed by the absence of these structures in previously 
shown SEM images of scaffolds.  
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Figure 13: Masson’s trichrome staining of electrospun scaffolds to confirm presence of 
ECM protiens in PLECM scaffold vs. PLLA only scaffold.  
3.1.6 Collagen and Elastin Quantification 
 Collagen and elastin were quantified with hydroxyproline and ninhydrin assays 
respectively, to determine the amount of the essential ECM proteins were in the scaffolds 
after electrospinning. Scaffolds were normalized with PLLA values that accounted for 
background. The amount of pure ECM powder within the 10 mg of scaffold was 
determined and used as a comparison. A large amount of collagen was found in the 
PLECM electrospun scaffolds but significantly less than seen in pure ECM. Elastin 
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amounts were determined using an amino acid quantification assay and showed more 
elastin content in the scaffolds than in pure ECM powder.  
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Figure 14: Collagen content shown by hydroxyproline quantification and elastin content 
shown by ninhydrin assay with electrospun scaffolds. Values normalized to PLLA 
background. Data are presented as mean +/- st. dev. Sample size varied between 9 and 17 
per group. **** p<0.0001 
3.2 Cell Viability and Proliferation 
3.2.1 Live/Dead Cell Viability Assay  
Live/Dead florescence imaging show a large amount of live (green) cells on both 
scaffolds but a significant many more dead (red) cells on the PLLA scaffolds (Figure 15). 
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There is also a difference between cell morphology on the two different scaffolds. Many 
more cells on the PLLA have a circular morphology and those that have extending 
appendages, have much smaller area coverage and extension. Quantification of several 
samples per group (Table 4) showed a consistent increase in dead cells on PLLA samples 
as compared to 35 mg/mL samples. 
 
Figure 15: Live/Dead imaging of HBSMCs on scaffolds. Live cells are stained green and 
dead cells are stained red. Sample size of 3 with at least 3 images taken of each sample. 
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  Average % Dead Average % Live 
35 mg/mL PLECM 0.34 +/- 0.22 99.66 +/- 0.22 
PLLA only 13.29 +/-11.95 86.71 +/- 11.95 
 
Table 4: Quantification of Live/Dead images. Average +/- st. dev. Averages taken 
from 9 to 11 images per group.  
3.2.2 Qualitative SEM Imaging 
SEM of HBSMCs on scaffolds cultured for 1 week show a significant amount of 
cell attachment and cell spreading on both scaffolds (Figure 16). There are qualitative 
differences in morphology and spreading between the scaffolds with PLECM and scaffolds 
without PLECM. Cells on the 35 mg/mL scaffold show confluent layering than those on 
PLLA only scaffolds.  
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Figure 16: SEM of HBSMCs on scaffolds. Week long culture of cells on scaffolds  
showing morphology and cell attachment. 
3.3 Cell phenotype 
3.3.1 qPCR 
To evaluate the impact that PLECM and electrospinning had on gene expression of 
contractile proteins and ECM production proteins, gene analysis was run alpha smooth 
muscle actin (αSMA), calponin 1 (CNN1), myosin heavy chain 11 (MYH11), and collagen 
1 (COL1 A1) with relative Cq values seen in Figure 17. All values are absolute data and 
are not relative to any housekeeping genes. In all cases, except for myosin heavy chain 11 
expression, HBSMCs on both types of electrospun scaffolds had increased expression over 
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PLLA and 35 mg/mL PLECM coatings. Similar expressions of αSMA were seen between 
PLLA and 35 mg/mL PLECM scaffolds but there seemed to be an increase in expression 
for the PLLA coating compared to the 35 mg/mL PLECM coating. In the case of CNN1, 
PLLA coatings and scaffolds showed more expression than their 35 mg/mL PLECM 
counterparts. Cells on scaffolds expressed less MYH11 than cells on both coatings but 
cells on PLLA coatings expressed more MYH11 than 35 mg/mL PLECM. A large increase 
was seen in the expression of COL1 A1 by cells on 35 mg/mL PLECM electrospun 
scaffold compared to PLLA only electrospun scaffolds. 
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Figure 17. qPCR data of HBSMCs on scaffolds and coatings for one week. Values shown 
are relative Cq values. Data are presented as mean +/- st. dev. Sample size varied between 
3 and 4 per group. Significance was defined as * p < 0.05 as indicated. 
3.3.2 Immunofluorescence. 
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 Phalloidin staining of F-actin in HBSMCs on PLLA and 35 mg/mL scaffolds in 
Figure 18 showed a large amount of cells attaching to both scaffolds, but there are also 
differences in morphology and actin distribution between the two different scaffolds. Cells 
on 35 mg/mL show a more spread out morphology with many projections with dense actin 
filaments. PLLA, in comparison has much less cell spreading with many cells still circular 
in morphology and only one to two projections per cell. Cells on PLLA also have actin 
filament staining mostly located centrally in the cell. 
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Figure 18: F-actin immunofluorescence staining of HBSMCs on scaffolds. Green 
(phalloidin) staining shows localization of F-actin throughout the cells on PLLA and 
35mg/mL scaffolds.  
50 
  
CHAPTER 4: Discussion 
Overall there is a consensus within the literature that natural ECM environments 
with a detailed architecture are vital for properly modeling an ASM environment. Past 
approaches have limitations preventing the replication of a full model with mechanical and 
biochemical relevance. In order to develop an in vitro model of airway smooth muscle that 
has superior biomimicry of the natural bronchial tissue, the major objective was to develop 
a biosynthetic scaffold with strength and ECM protein composition. More specifically, our 
goals were to develop an electrospun scaffold consisting of a synthetic polymer and pig 
lung extracellular matrix (PLECM), verify the presence of key ECM components post-
solublization and post-electrospinning, and finally investigate whether the scaffold can 
support SMC growth and maintain the smooth muscle contractile phenotype. The results 
led to the development of a novel nanofibrous mat on which HASMCs were able to grow 
and interact with the essential ECM proteins. ECM concentration and electrospinning 
parameters are critical for the structural and bioactive properties held by the scaffold. This 
is important because fibers resembling natural small airway ECM in size and composition 
directly effects cell phenotype. We can use decellularized airway tissue as a guide for 
scaffold topographies ranging in porosity and fiber density for each region. To ensure the 
smooth muscle cell interactions are physiologic, natural cell microenvironments for each 
cell type must be present with nano to micro sized fibers that provide the ability for cell 
alignment, directing smooth muscle cell growth in the circumferential direction around the 
airway for constriction purposes [35].  This data demonstrates the potential the 
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PLLA/PLECM electrospun scaffold has as a novel and superior in vitro model for the 
study of normal SMC interactions, disease modeling, or drug delivery research.  
Current in vitro models of lung cellular environments using polymeric scaffolds do 
not fully represent the in vivo tissue environment. Studies done with fully synthetic 
polymers lack the natural ECM components needed for proper signaling with lung cells 
[42]. By adding the processing technique of electrospinning to polymers, it can offer many 
benefits of structural recognition [36] but lack biological signaling for proper physiological 
mimicking. Electrospinning of natural ECM elements to increase bioactivity has been 
extensively researched but most have only one or two ECM components represented [29], 
[30]. These engineered scaffolds have drawbacks because of the lack of a wide range of 
ECM components at a specific ratio present in organ specific decellularized tissue [22]. 
Other subpar in vitro models also struggle with the inability to retain growth factors, giving 
an incomplete representation of airway in vivo ECM environments [38]. A large amount of 
information is hidden in signaling molecules and binding sites within the extracellular 
environment that combine to form a unified complex picture that can only maintain tissue 
specific differentiation with all of the signaling players [43], [44]. Decellularized materials 
without further processing can also pose limitations because of uncontrollable shape, 
mechanical properties, and degradation rates. Developing a platform that permits the 
culturing of SMCs for the accurate testing of therapeutic and toxicity responses to drugs 
will open the doors to more effective drug testing and understanding of the natural 
cell/ECM interaction in diseased or normal states. In this study, we have designed a 
platform with these qualities by combining the tailorable structural support of PLLA with 
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sufficient ECM components for optimized cell attachment and tissue specific signaling 
[26].  
The PLECM/PLLA scaffolds were successfully developed from decellularized pig 
lung [40] dissolved into HFP to allow for evaporation of the solvent during the 
electrospinning process. HFP was chosen because of its use in various prior studies [45]. 
Its boiling point of 61 degrees makes it prone to evaporation, a characteristic that is 
essential for electrospinning and having dry fibers as a final product [30]. This electrospun 
mixture allows for an increase of mechanical strength, control of ECM component release 
[37], and electrospinning consistency as compared to ECM alone. ECM concentration was 
chosen based upon a previously published collagen electrospinning protocol also using 
HFP [30] that showed concentration dependence associated with fiber diameter. Similar 
concentrations were used with minor modifications in electric potential based on the 
formation of a Taylor cone with the selected materials and quality of the final scaffolds. 
After optimization, the resulting concentration was determined to be 17.5 mg/mL and 35 
mg/mL to give a mostly uniform nonwoven fibrous mat based on electrospinning 
properties alone. After further investigation, we saw in increase in the cell viability and 
attachment with the higher concentration of 35 mg/mL leading us to eliminate 17.5 mg/mL 
as an optimal concentration and removing it from all experiments. 
We then moved on to optimizing properties for the culture of smooth muscle cells. 
The goal was to have a randomized fiber arangment of medium sized fibers resembling 
those found in the smooth muscle layer of airway wall, shown in figure 8E. The scaffold 
created by electrospinning the solution at 27 cm with a 4.5 ml/hr flow rate, and 19G needle 
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produced the most desirable fiber diameter. Looking closer into the region of the airway 
where smooth muscle is found in the lung figure 8F, fiber distribution is similar to what we 
have created with a difference in fiber shape. Natural ECM fibers have a coiled appearance 
when cut leading us to believe that fibers are naturaly under tension. Future investigations 
would be to construct fibers resembling the decellularized ECM by fabricating fibers under 
tension.  
Another future investigation would be to achieve smaller fiber diameter scaffolds to 
optimized growth for epithelial cells. The most significant decrease in fiber diameter was 
seen when PLLA concentration was decreased. While this seemed encouraging, we were 
unsure about the quality of this scaffold because there seemed to be issues with the 
PLECM stopping up the syringe. We concluded that the smaller fiber diameter was caused 
by a decrease in the available opening for PLLA to exit while the PLECM was clogging 
the syringe. Additional troubleshooting and investigating of the scaffold developed from 
the lower concentration of PLLA will need to be done in the future to see if this is a viable 
option for multicellular culture. If this could be achieved, our hopes would be to form a 
biphasic scaffold [35] in the future. 
The most abundant ECM proteins in the lungs are collagen, mostly collagen type I, 
III, IV, and V, and elastin [30], [46]. The majority of the proteins just mentioned have a 
slightly larger nanometer sized fiber, causing cells to be accustomed to recognizing the 
majority of larger fibers and less of smaller fibers such as fibronectin, laminin, and other 
less frequent constituents. Many studies stress the importance of a distribution of nanofiber 
diameter that closely resembles the distribution in the specific anatomical ECM being 
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modeled [30]. Cells have the ability to recognize varying levels of protein structures, 
including, collagen fibrils ranging from 260 and 410 nm [47], elastin filaments from 3-4nm 
[48], elastin fibrils from 200 and 3000 nm [49], and smaller collagen fibers of just 50nm 
(collagen type 1, 4). With the use of SEM, it was confirmed that the electrospinning 
parameters chosen for specific concentrations of PLECM generated nano to micro-sized 
fibers with an average fiber size of 793.7 nm, similar to a collagen fibril or elastin fibril. 
The range of fiber sizes varied from 54 nm to 4702.1 nm with a much higher occurrence 
between 250 nm and 750 nm. With this fiber distribution the cells are experiencing the 
structural signals from all fiber sizes resembling all ECM proteins but with a much higher 
presence of collagen like fibers as is seen in the natural lung tissue where 90% of the dry 
weight is collagen [38].  
Incorporating ECM proteins into synthetic scaffolds not only disrupts the 
mechanical strength of the synthetic polymer, but since the DPLECM already possess a 
similar modulus to natural tissue, it counteracts the high modulus of PLLA. Research has 
strongly supported the idea that tissue engineering scaffolds must possess mechanical 
characteristics matching the natural tissue to avoid failure or disruption of natural 
processes [50]. In an environment as dynamic as the lungs, cells sense the response of the 
surrounding ECM to mechanical loads spatially and temporally for the maintenance of 
natural signaling cascades and phenotype. Decrease of the scaffolds average elastic moduli 
by 34.11 MPa with the addition of PLECM, partially returns the scaffold towards the realm 
of intact lung tissue possessing a modulus of 0.5 kPa [51]. According to what is known 
about mechanical characteristics of decellularized and whole lung tissue, this value is what 
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should be expected for small airway scaffolds because the addition and remodeling of cells 
should then greatly decrease scaffold stiffness even further.  
Addition of cells to our scaffolds for one week decreased the modulus of PLLA to 
16.53. Naturally, the decrease in elastic modulus by remodeling would be caused by matrix 
metalloproteinases (MMPs) [52]. The breakdown of the PLLA fibers by these enzymes is 
questionable because of the lack of cleavage sites within the synthetic polymer. It is 
evident that there has been some breakdown to the PLLA structure, seen by decreased 
elastic modulus, but this could have been caused by a decrease in pH within the media 
from cellular metabolic waste. Evidence from gene expression of collagen 1 does support 
the theory that remodeling is still occurring but the breakdown of the fibers by the 
HBSMCs may not be taking place. It is also important to note that in vivo there would be 
an increase in the elastic modulus caused by ECM production. This is not seen here 
because the collagen and other ECM proteins that are being produced are not cross-linked 
because of the absence of Vitamin C. In the future, addition of vitamin C to the culture 
would be needed to see the true effect of remodeling by the cells. The same situation may 
be occurring within the 35 mg/mL scaffolds because of the PLLA within them but there is 
a presence of natural ECM components and their cleavage sites that would allow for some 
MMP breakdown. However, the data showed that when cells were cultured on 35 mg/mL 
scaffolds (14.03 MPa), the modulus did not change much from the 35 mg/mL scaffolds 
without cells. The insignificant change from 35 mg/mL scaffolds without cells to the 35 
mg/mL scaffolds with cells was caused by the exclusion of many samples because they 
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were too weak to be loaded into the MTS machine. Future studies will include more 
precise measures of mechanical properties.  
Since there were no problems loading the PLLA scaffolds with cells or the few 
thicker 35mg/mL scaffolds, it can be concluded that 35 mg/mL scaffolds may have an 
elastic modulus well below 16.35 MPa and therefore may have a much closer mechanical 
strength to natural lung tissue. We predict that with extended culture periods there will be 
more remodeling as more of the polymer is replaced with ECM produced by the ASM 
cells. The results showed PLLA only scaffolds also having beneficial remodeling with a 
significantly lower the average modulus to 16.35 MPa, but PLECM scaffolds started out at 
a more realistic modulus allowing it to take less cellular remodeling to reach the natural 
mechanical properties. By having a model that more accurately resembles the mechanical 
properties, the scaffolds will encourage realistic ECM deposition by the HBSMCs and 
maintain cellular phenotypic responses. The results showed that the addition of the 
PLECM not only improved the mechanical properties but also the physical hydrophilicity 
of the scaffold. Similar studies done with electrospinning bone ECM have shown that as 
more ECM is introduced into a composite, the less hydrophobic the scaffold will become 
[37] because the ECM is hydrophilic which induces cell attachment and proliferation [53]. 
Delving further into ECM scaffolds ability to increase attachment and behave 
accurately as an in vitro model, the question is, are all of the ECM proteins intact, 
prevalent, and recognizable post electrospinning? There is some concern about ECM 
proteins polymerizing with the PLLA during the electrospinning process, leaving binding 
sites and full proteins unnoticeable to the cells. Our research has found that after the 
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decellularization process there is still the presence of several smaller fragments of larger 
ECM components and possibly whole ECM proteins, just as was seen in other studies 
using this same decellularization procedure [40]. The data also determined whether the 
harsh solvent or electrospinning process causes any damage or masking of key proteins 
attachment sites or growth factors. Intact and decellularized tissue was used as a 
comparison to the amount of ECM components lost in the liquid nitrogen milling, HFP 
treatment, and electrospinning. Comparing samples treated with HFP to the DPLECM and 
DPLECM powder, there are significantly less bands after exposure to HFP because of 
HFP’s ability to denture, open, and break apart proteins. There is much less difference in 
the amount of bands between the DPLECM powder in HFP and 35 mg/mL, allowing us to 
conclude that the process of electrospinning causes little effect to ECM proteins. There are 
still detectable amounts of proteins, either fragments or full, within the PLECM/PLLA 
electrospun scaffold that can offer various natural signaling cascades for the maintenance 
of smooth muscle phenotype. In summary, HFP denatures and unfolds proteins as 
compared to decellularized tissue and powder, but the resulting fragments of larger 
proteins are detectable after electrospinning. In future experiments, blotting the gels and 
probing with antibodies to membranes will allow for identification of specific ECM 
proteins. 
With collagen and elastin being the most abundant proteins within the ECM [46], 
confirmation of these proteins in our scaffold is vital to determining the level of 
recognition the cells have with our scaffolds. Hydroxyproline and ninhydrin assays, which 
were performed to quantify both collagen and elastin, respectively, prove that there is a 
58 
  
significant amount of collagen and elastin in PLECM scaffolds. Collagen quantifications 
showed a decrease in collagen content as compared to ECM powder due to loss of collagen 
during the electrospinning process. Elastin, in contrast, was more prevalent in the 
electrospun scaffold than in pure ECM powder. This could have been caused by the 
electrospinning properties of elastin, such as charge or molecular weight that would ensure 
there is a large yield of elastin compared to other ECM proteins. Another possibility for 
this result could be the quantification method of detecting amino acids. There may have 
been a difference in the breakdown of the scaffolds and the ECM powder into amino acids. 
We do expect that most of the collagen and elastin quantified here would be broken down 
versions of these proteins because of the lack of banding for the electrospin scaffolds 
within the SDS-PAGE where collagen (200 kD) and elastin (81 kD) would be found.    
The presence of these key ECM proteins was further confirmed by Masson's 
trichrome staining of ECM confirming the presence of collagen and elastin throughout 
35mg/mL scaffold. Large clumps of scaffold with significant ECM staining are seen 
throughout the images but we have concluded that these are sectioning artifacts based on 
their absence in all other imaging of the scaffolds such as SEM. Staining offered us a more 
in depth look into the location and amount of the ECM proteins throughout the scaffold 
and fiber. Having well dispersed proteins throughout the fiber shows there will be an even 
released of proteins during degradation as well as randomized disbursement throughout the 
fiber for cell attachment. Our ECM stained histology, SDS-PAGE, and elastin and collagen 
quantification showed that we do have ECM components detectable within the scaffolds 
post-fabrication. 
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Following the characterization of the PLLA/PLECM scaffold and the confirmation 
of recognizable ECM proteins, the second objective of this research was to investigate the 
scaffolds ability to support growth, increase attachment, and differentiation of primary 
human bronchial smooth muscle cells. Previous studies using decellularized ECM have 
shown increased cell adhesion and proliferation in the case of urinary bladder regeneration 
with a natural and synthetic polymer composite [54]. Results of this study have shown 
similar results even with a more complex soft tissue to be modeled. Scanning electron 
microscopy (SEM) confirmed that both scaffolds are capable of supporting smooth muscle 
growth with a confluent layer on each. A slight change in morphology and the extent of 
confluency was observed but this change may not be caused by a cellular process. There is 
a possibility that the changes in morphology and confluency on PLLA may be caused by a 
processing artifacts from drying. PLLA and other polymers shrink when dried, breaking 
the attachment sights of the cells and causing the breakage seen in the PLLA scaffold. This 
processing artifact did not seem to affect the cells on the 35 mg/mL PLLA/PLECM 
scaffold leading us to believe there is a difference with either the scaffolds properties or the 
cellular layers. There are three possible explanations for this difference. First, there could 
be little drying artifact and the differences seen are a true morphological difference 
between the cells. Another explanation would be that multiple layers of cells had built up 
on the PLLA/PLECM scaffold because of the impact the PLECM has on proliferation, 
then the top cells seen on ECM would not have been affected by the pulling of the PLLA 
fibers during drying. Lastly, the PLECM could disrupt the PLLA, lessening the severity of 
the drying artifact. Morphological differences and signaling changes of smooth muscle 
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cells with the addition of PLECM is seen in various experiments throughout this research, 
leading to the conclusion that the visual difference seen in the SEM imaging may not be 
fully accurate because of processing artifacts but other data would suggest there would be 
some morphological changes.  
It is also important to notice the cellular alignment achieved on both scaffold types. 
The alignment achievable by the nanofibrous mat without alignment of the scaffold fibers 
will allow for manipulation of HASMCs into a pattern that will likely promote contraction 
and dilation of the tube in a circumferential manner [38]. The ability of these electrospun 
scaffolds to support smooth muscle growth was also supported by Live/Dead staining with 
a low amount of smooth muscle cell death on 35 mg/mL scaffolds as compared to PLLA 
with an average 13% more live cells per sample. Increased cell death and a noticeable 
rounded morphology can be attributed to the lack of signaling proteins in PLLA.   
    There have been studies of decellularized ECM (DECM) incorporation into 
nanofiber scaffolds to manipulate stem cell differentiation [37]. From this work and others 
supporting the positive effect that DECM has on cell phenotype, expression of contractile 
markers such as αSMA, CNN1, and MYH11 should increase. From our results, similar 
expressions of these genes except MYH11 were seen between PLLA scaffolds and 35 
mg/mL scaffolds. With respect to PLLA and PLECM coatings, PLLA has an increased 
expression of contractile proteins that does not support our hypothesis. Comparing 
coatings to electrospun scaffolds provides insight into the role of the topography in 
phenotypic signaling. Overall there is an increase in contractile protein expression with the 
exception of MYH11, with electrospun scaffolds. This supports the idea that a fibrous 
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nanostructure is important in the maintenance of contractile phenotype. While not all of the 
qPCR data supports our hypothesis, phalloidin staining of F-actin shows a significant 
difference in arrangement and distribution throughout the cells on PLECM/PLECM 
scaffolds compared to PLLA only scaffolds. The morphology of the cells and expression 
of F-actin help to support the idea that PLECM affects cell phenotype.  
Throughout the body, active remodeling of ECM occurs in homeostasis, 
development, and the healing process [55]. The significant increase in expression of genes 
responsible for the production of important lung ECM proteins such as collagen 1 (COL1 
A1) on PLECM/PLLA scaffolds can be attributed to normal remodeling of the scaffold. 
Collagen 1 production is much less prevalent in PLLA only materials as well as coatings 
with PLECM. It can be concluded that both ECM structural organization and bioactivity 
are needed for proper ECM remodeling to occur.  
Overall, we were able to develop a fiber diameter distribution most closely 
resembling the distribution seen in the natural small airway ECM. This is shown clearly in 
SEM images of the scaffolds and decellularized airway tissue. This research confirmed that 
PLECM electrospun into the scaffolds results in ECM fragments that are detectable post-
electrospinning, seen by SDS-PAGE, Masson’s trichrome staining, and collagen and 
elastin quantification assays. Both elastic modulus and hydrophobicity were confirmed to 
have decreased drastically to more closely mimic the natural tissue. Lastly we were able to 
show an increase in bioactivity of the PLECM/PLLA scaffold through cell culture of 
HBSMCs onto the scaffolds. Cell morphology and viability increased on PLECM/PLLA 
scaffolds, seen by live dead, SEM, and phalloidin imaging. Gene analysis of contractile 
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proteins gave insight into the contractility of cells on the scaffolds and concluded that the 
nanostructure affects the phenotype and ECM production of HBSMCs. 
Our future work will include the development more specific bronchiole models to 
include mechanical stresses with the use of a bioreactor. This research will also be applied 
to a multicellular model that takes this proven scaffold and modifies fiber diameter and 
denseness to create optimal epithelial and fibroblast environments for a whole bronchiole 
tissue model. The current scaffold has shown to be an appealing scaffold for smooth 
muscle modeling and tissue engineering which can eventually be expanded to investigate 
cell-cell interactions among multiple cell types as well as the role they play in diseased 
states.  
 
63 
  
CHAPTER 5: Conclusion  
 In this study, we sought to evaluate the potential of a copolymer electrospun 
nanofiber scaffold consisting of poly-L-lactic acid (PLLA) and decellularized pig lung 
extracellular matrix (PLECM) as an in vitro airway smooth muscle (ASM) model. We 
hypothesized that electrospun scaffolds composed of PLECM and PLLA would enhance 
the bioactivity, mechanical properties, and architecture as compared to scaffolds solely 
composed of PLLA or PLECM. We were able to verify the presence of key ECM 
components post electrospinning through histological staining and SDS-PAGE methods. 
Confirmation of ECM proteins supports the evidence that the bioactivity of this scaffold 
can be attributed to cell recognition of ECM protein fragments. Additionally, by creating a 
scaffold that was more similar in mechanical properties and hydrophilicity to human lung 
tissue, both cell attachment and maintenance of ASM phenotype increase, making it a 
more beneficial model of the physiological environment. Overall, the electrospun PLLA 
and PLECM scaffolds promote growth and attachment of HBSMCs, with proves that this 
combination of natural and synthetic materials are appealing for a tunable in vitro ASM 
model for investigation of natural or disease states.  
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CHAPTER 6: Supplemental Data and Future Directions 
 The future directions of this project include the broadening of this scaffold’s 
possible applications. For this scaffold to be used for the modeling of other airway diseases 
or as regenerative material for lung regrowth after injury, the scaffold must be able to 
support growth of more cell types than smooth muscle cells. This scaffold’s structural 
characteristics are currently optimized for the growth and differentiation of smooth muscle 
cells, but if the structural properties were modified, this scaffold could be beneficial for the 
growth of other cell types. DPLECM includes ECM proteins of the entire small airway and 
therefore should maintain differentiation of all lung cell linages. As a supplement to the 
smooth muscle modeling thesis, my research investigated the optimization of this scaffold 
for mostly Small Airway Epithelial cells (SAECs) but also other airway cell types such as 
human mesenchymal stem cells (HMSCs), lung fibroblasts, and immortalized lung 
epithelial cells (A549s).  
 The first step of SAEC investigation was to look at the response of SAECs on the 
original scaffold. Figure 19 includes SEM imaging of SAECs cultured on both PLLA and 
PLECM/PLLA scaffolds for 48 hours showing that both scaffolds support SAEC 
attachment and growth. 35 mg/mL PLECM scaffold show a slight increase in cell 
spreading achieving a cobblestone effect compared to the PLLA only scaffold but, overall, 
there does not seem to be an increase in cell attachment between the two.  
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Figure 19: SEM of SAECs on original PLLA/PLECM scaffolds cultured for 48 hours.  
 SEM of SAECs looked to be encouraging results but was not enough evidence to  
confirm this scaffold as a effect model for epithelial modeling. To quantify cell 
proliferation, Picogreen (DNA) proliferation assay was run on SAECs in the same 
condition and we were able to quantitativly show that there was an increase in cellular 
proliferation as shown in Figure 20. In this figure, it is easy to determine that PLECM had 
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a significantly positive affect on proliferation. We also determined that 35 mg/mL showed 
to be a more benifical concentration of PLECM over 17.5 mg/mL, leading to the 
disscontinution of 17.5 mg/mL scaffolds in our experiments.  
 
Figure 20: Picogreen (DNA) proliferation assay on SAECs cultured on scaffolds for 48 
hours. 6 to 8 samples for each group were seeded with 30,000 cells/cm3. Values 
normalized to scaffolds without cells. **** p<0.0001 
 Once the bioactivity was examined this far, a coculture study was done with 
SAECs and HBSMCs. HBSMCs were cultured one week before seeding SAECs ontop for 
one more week. The resulting 2 week culture was imaged with phalloidin and DAPI to 
show the interaction and organization of these two cell types, seen in Figure 21.  
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Figure 21: Cocutlure of SAECs and HBSMCs on 35 mg/mL scaffold. HBSMCS were 
cultured for 1 week before adding SAECs for an additional week and stained with 
Phalloidin (green) and DAPI (blue). 
 After coculture studies, more bioactivity and pheotyping studies were done with 
SAECs on the orginal scaffolds showing results that were no longer supporting our 
hypothesis that our PLECM/PLLA scaffold would promote SAEC growth. The design of 
the scaffold then had to be modified to decrease fiber diameter and increase fiber density to 
more resemble the basement membrane [35]. We tried to more closely mimic a basement 
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membrane by applying a previously tested [39] The scaffold and hydrogel material has a 
surface with a denser arrangment of fibers with surrounding environment with high water 
content, as seen in natrual tissue. Having the original electrospun scaffold on the oppisite 
side kept the fiber structure and aragement most benificual for smooth muscle culture if 
coculture studies were desired in the future. The resulting scaffold (Figure 22) was 
fabricated by adding a pregel solution [39] and allowing to crosslink at 37° C and cultured 
with SAECs for 48 hours to assess attachment and morphology (Figure 23). The scaffold 
that was produced showed and increased density to allow for a denser arrangement of 
fibers. SEM of cultured cells on hydrogel scaffolds showed that it supported SAEC growth 
but with less cell spreading and attachment than expected.  
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Figure 22: Electrospun PLECM/PLLA scaffold with addtion of ECM hydrogel [39]. 
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Figure 23: Culture of SAECs onto Electrospun PLECM/PLLA scaffold with hydrogel 
surface. 
 In order to test this scaffold as a model for applications that include the modeling of 
cell types other than smooth muscle cells, we investigated the ability of the scaffold to 
support airway cell types such as HMSCs, lung fibroblasts, and A549s. HMSCs were 
cultured onto scaffolds in HMSC high performance media (Rooster Bio, Figure 24) in 
order to evaluate if the bioactivity of the scaffold alone could differentiate the 
mesenchymal cells into a definite airway cell type like smooth muscle cells. Cell 
phenotype was difficult to definitively determine so we relied on qPCR to see if we were 
seeing an increase in contractile phenotypes as compared to HMSCs not on scaffolds. 
From the qPCR data (not shown) we were not able to conclude that phenotype was being 
71 
  
driven by the scaffold and more troubleshooting and testing must be done in the future to 
investigate the effect the scaffold has on HMSCs. 
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Figure 24: HMSCs cultured onto scaffolds to show stem cell differentiation encouraged by 
scaffold bioactivity.  
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 To ensure that we looked at the behavior of most cell types within the lung with the 
scaffold, we also tested the interaction of lung fibroblasts (Figure 25-A) and A549 cells 
(Figure 25-B). As expected with these two hardy cell types, there was good cell attachment 
and cell spreading on the scaffold. Especially with the lung fibroblasts because of their 
similar structural preferences as smooth muscle cells [35], the similar behavioral response 
was expected. 
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Figure 25: Culture of lung fibroblasts (A) and A549 cells (B) onto 35 mg/mL PLECM 
scaffolds.  
 We also looked into bettering our small airway model by creating a more holistic 
and physiologically environment for culturing the electrospun scaffolds in. The first step 
was to develop a 3D tube shaped scaffold that more closely resembled the 
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microarchitecture of the small airways shown in Figure 26-A. A bioreactor prototype was 
also developed for seeding and culturing of airway cell types was developed and can be 
seen in Figure 26 B-C. It was comprised of two chambers, on to hold the bronchiole 
scaffold and the other was a media reservoir. It was equipped with in and out tubing 
allowing flow between the two holding chambers. This prototype was run with 1.3 million 
HBSMCs in culture for two weeks. Resulting scaffolds were imaged by SEM but very few 
cells had attached. We concluded that the flow rate and bioreactor surface area was not 
optimal for cell culture. Other bioreactor options will be looked at in the future to allow for 
cell seeding and physiologically relevant culturing that includes airflow through the inside 
of the tube with pulsatile pressure and media around the outside to function a blood 
circulation.  
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Figure 24 
Figure 26: Initial 3D electrospun tube and bioreactor design and setup. 3D electrospun 
scaffold resembling shape and diameter of bronchiole (A). Planned prototype set up with 
all all parts labeled (B). The actual set up of the bioreactor in the incubator (C). 
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